Rotterdam, Netherlands

Johannes Theodorus Den Dunnen

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 164(Granted Patents)


Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Johannes Theodorus Den Dunnen

Introduction

Johannes Theodorus Den Dunnen is a notable inventor based in Rotterdam, Netherlands. He has made significant contributions to the field of molecular biology, particularly in the modulation of pre-mRNA splicing. With a total of 4 patents to his name, Den Dunnen's work has the potential to impact therapeutic approaches for genetic diseases.

Latest Patents

Den Dunnen's latest patents focus on the modulation of exon recognition in pre-mRNA by interfering with the secondary RNA structure. One of his inventions relates to oligonucleotides designed to induce skipping of exon 53 of the dystrophin gene. This invention provides methods for generating oligonucleotides that can skip specific exons in pre-mRNA, thereby excluding them from the resulting mRNA. Additionally, he has developed methods for altering the secondary structure of mRNA to interfere with splicing processes. These innovations also include pharmaceutical compositions and methods for inducing skipping of multiple exons in pre-mRNA.

Career Highlights

Den Dunnen is affiliated with Academisch Ziekenhuis Leiden, where he continues to advance his research and innovations. His work is crucial in the development of new therapeutic strategies for diseases linked to genetic mutations.

Collaborations

He has collaborated with notable colleagues such as Garrit-Jan Boudewijn Van Ommen and Judith Christina Theodora Van Deutekom. Their combined expertise enhances the research efforts in the field of molecular genetics.

Conclusion

Johannes Theodorus Den Dunnen's contributions to the field of molecular biology through his innovative patents demonstrate his commitment to advancing medical science. His work holds promise for future therapies targeting genetic disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…